Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.090
-0.030 (-2.68%)
Nov 21, 2024, 1:19 PM EST - Market open
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 5.67, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 420.18% from the current stock price of 1.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HRTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +266.97% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +358.72% | Sep 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +358.72% | Aug 7, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +542.20% | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +358.72% | May 16, 2024 |
Financial Forecast
Revenue This Year
151.37M
from 127.04M
Increased by 19.15%
Revenue Next Year
183.60M
from 151.37M
Increased by 21.29%
EPS This Year
-0.11
from -0.80
EPS Next Year
0.00
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 160.1M | 193.1M | 233.6M | ||
| Avg | 151.4M | 183.6M | 225.2M | ||
| Low | 141.2M | 171.5M | 214.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.0% | 27.6% | 27.2% | ||
| Avg | 19.1% | 21.3% | 22.6% | ||
| Low | 11.2% | 13.3% | 16.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.08 | 0.03 | 0.28 | ||
| Avg | -0.11 | 0.00 | 0.24 | ||
| Low | -0.16 | -0.05 | 0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 11,696.3% | ||
| Avg | - | - | 9,921.5% | ||
| Low | - | - | 8,147.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.